Brexpiprazole for Alzheimer's Agitation

What Is Agitation in Alzheimer's Disease and Why Does It Matter?

Agitation in Alzheimer's disease is more than occasional irritability. The International Psychogeriatric Association defines it as persistent emotional distress accompanied by excessive motor activity, verbal aggression, or physical aggression that causes excess disability beyond what cognitive decline alone would predict. Research suggests these symptoms emerge in roughly half of patients at some point in their illness, often intensifying in moderate to severe stages.

Beyond the suffering it causes the patient, agitation is among the most powerful predictors of institutionalization and is consistently ranked by caregivers as harder to manage than memory loss itself. Until recently, clinicians relied on off-label use of antipsychotics, antidepressants, or sedatives—each carrying meaningful risks in older adults with dementia. The arrival of a labeled treatment marked a shift from improvised prescribing to evidence-based, regulator-reviewed therapy.

How Does Brexpiprazole Work and What Did the Trials Show?

Brexpiprazole's pharmacology differs from older antipsychotics. As a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, it stabilizes rather than fully blocks dopaminergic signaling, a profile that may translate into a lower risk of extrapyramidal side effects compared with first-generation agents. Its strong 5-HT2A antagonism is thought to contribute to calming effects without heavy sedation in many patients.

The FDA approval rested on randomized, double-blind, placebo-controlled studies in patients with Alzheimer's-related agitation. Across the program, brexpiprazole-treated patients showed greater reductions on the Cohen-Mansfield Agitation Inventory total score than placebo over 12 weeks. Common adverse events reported in the trials included headache, dizziness, urinary tract infection, and somnolence, while serious risks tracked the broader antipsychotic class.

What Are the Risks and Who Should Consider This Treatment?

The boxed warning is unchanged for brexpiprazole: across antipsychotic studies in older adults with dementia, treated patients had higher rates of cardiovascular and infectious deaths than those on placebo. Regulators allowed the labeled indication because the trials showed a measurable benefit on a serious symptom, but the warning explicitly cautions that the drug is not approved for dementia-related psychosis without agitation.

In clinical practice, guidelines from organizations including the American Psychiatric Association and the Alzheimer's Association recommend non-pharmacologic interventions—such as identifying triggers, structured routines, music therapy, and addressing pain or infection—as first-line management. Pharmacotherapy is reserved for cases where behavioral approaches fail and agitation poses a risk of harm. Decisions should be shared with families, with periodic reassessment to determine whether the medication can be tapered.